MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Summary

This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). MiRisten may stop the growth of cancer cells by blocking some of the molecules needed for cell growth. Giving miRisten may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.

Timeline

Start

2025-10-24

Primary completion

2028-03-01

Completion

2028-08-01

Outcome

Outcome not reported

Stopped: “Pending Interim Analysis”

Drugs

Indications